| Potently neutralizing and protective human antibodies against SARS-CoV-2 SJ Zost, P Gilchuk, JB Case, E Binshtein, RE Chen, JP Nkolola, A Schäfer, ... Nature 584 (7821), 443-449, 2020 | 1109 | 2020 |
| Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein, AN Loes, SK Hilton, ... Cell host & microbe 29 (1), 44-57. e9, 2021 | 1052 | 2021 |
| Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies RE Chen, X Zhang, JB Case, ES Winkler, Y Liu, LA VanBlargan, J Liu, ... Nature medicine 27 (4), 717-726, 2021 | 898 | 2021 |
| An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies LA VanBlargan, JM Errico, PJ Halfmann, SJ Zost, JE Crowe Jr, LA Purcell, ... Nature medicine 28 (3), 490-495, 2022 | 712 | 2022 |
| Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains SJ Zost, K Parkhouse, ME Gumina, K Kim, S Diaz Perez, PC Wilson, ... Proceedings of the National Academy of Sciences 114 (47), 12578-12583, 2017 | 529 | 2017 |
| Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein SJ Zost, P Gilchuk, R Chen, JB Case, JX Reidy, A Trivette, RS Nargi, ... Nature medicine 26, 1422-1427, 2020 | 472 | 2020 |
| Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail J Dong, SJ Zost, AJ Greaney, TN Starr, AS Dingens, EC Chen, RE Chen, ... Nature microbiology 6 (10), 1233-1244, 2021 | 372* | 2021 |
| Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein N Suryadevara, S Shrihari, P Gilchuk, LA VanBlargan, E Binshtein, ... Cell 184 (9), 2316-2331. e15, 2021 | 364 | 2021 |
| Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection ES Winkler, P Gilchuk, J Yu, AL Bailey, RE Chen, Z Chong, SJ Zost, ... Cell 184 (7), 1804-1820. e16, 2021 | 317 | 2021 |
| A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine NC Wu, SJ Zost, AJ Thompson, D Oyen, CM Nycholat, R McBride, ... PLoS pathogens 13 (10), e1006682, 2017 | 246 | 2017 |
| Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies N Pardi, K Parkhouse, E Kirkpatrick, M McMahon, SJ Zost, BL Mui, ... Nature communications 9 (1), 3361, 2018 | 233 | 2018 |
| In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains RE Chen, ES Winkler, JB Case, ID Aziati, TL Bricker, A Joshi, TL Darling, ... Nature 596 (7870), 103-108, 2021 | 226 | 2021 |
| Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013–2014 influenza season SL Linderman, BS Chambers, SJ Zost, K Parkhouse, Y Li, C Herrmann, ... Proceedings of the National Academy of Sciences 111 (44), 15798-15803, 2014 | 226 | 2014 |
| Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin JM Lee, R Eguia, SJ Zost, S Choudhary, PC Wilson, T Bedford, ... Elife 8, e49324, 2019 | 87 | 2019 |
| Immunodominance and antigenic variation of influenza virus hemagglutinin: implications for design of universal vaccine immunogens SJ Zost, NC Wu, SE Hensley, IA Wilson The Journal of infectious diseases 219 (Supplement_1), S38-S45, 2019 | 78 | 2019 |
| Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals EC Chen, P Gilchuk, SJ Zost, N Suryadevara, ES Winkler, CR Cabel, ... Cell Reports 36 (8), 2021 | 72 | 2021 |
| Human influenza A virus hemagglutinin glycan evolution follows a temporal pattern to a glycan limit MO Altman, M Angel, I Košík, NS Trovão, SJ Zost, JS Gibbs, L Casalino, ... MBio 10 (2), 10.1128/mbio. 00204-19, 2019 | 69 | 2019 |
| Comparison of Human H3N2 Antibody Responses Elicited by Egg-Based, Cell-Based, and Recombinant Protein–Based Influenza Vaccines During the 2017–2018 Season S Gouma, SJ Zost, K Parkhouse, A Branche, DJ Topham, S Cobey, ... Clinical Infectious Diseases 71 (6), 1447-1453, 2020 | 36 | 2020 |
| Identification of antibodies targeting the H3N2 hemagglutinin receptor binding site following vaccination of humans SJ Zost, J Lee, ME Gumina, K Parkhouse, C Henry, NC Wu, CCD Lee, ... Cell reports 29 (13), 4460-4470. e8, 2019 | 29 | 2019 |
| Pan-ebolavirus protective therapy by two multifunctional human antibodies P Gilchuk, CD Murin, RW Cross, PA Ilinykh, K Huang, N Kuzmina, ... Cell 184 (22), 5593-5607. e18, 2021 | 24 | 2021 |
